# Genotype-Phenotype Correlation in Antimicrobial Resistance

## Quick Answer

- Genotypic resistance gene detection and phenotypic susceptibility testing can disagree because gene presence does not guarantee gene expression, and phenotypic resistance can arise from mutations, efflux pumps, or heteroresistance that genomic screens miss.
- When discordance appears, repeat the phenotypic test with a validated method, check the resistance gene for promoter or structural mutations, and consider combination resistance mechanisms before reporting a final result.
- No single approach resolves all discrepancies, and clinical decisions should integrate both genotypic and phenotypic data with local epidemiology and patient context.

## At a Glance

| Discordance Type | Common Cause | Interpretation Approach | Clinical Action |
|---|---|---|---|
| Gene present, susceptible phenotype | Gene not expressed, promoter mutation, or silent carriage | Confirm gene identity and check expression context | Report phenotypic result, consider induction testing if clinically relevant |
| Gene absent, resistant phenotype | Efflux pump overexpression, porin loss, target mutation | Perform phenotypic confirmation and investigate alternative mechanisms | Treat based on phenotypic susceptibility, escalate to reference method |
| Gene present, resistant phenotype | Active resistance mechanism, gene expression confirmed | Concordant result, validate with phenotypic testing | Guide therapy with phenotypic data, monitor for treatment failure |
| Variable phenotype across replicates | Heteroresistance or mixed population | Repeat testing, perform population analysis if available | Use highest observed MIC for clinical decisions, consider combination therapy |

## Understanding Genotype-Phenotype Correlation in Antimicrobial Resistance

Antimicrobial resistance arises through genetic changes that alter bacterial susceptibility to therapeutic agents. The relationship between the genetic determinants of resistance and the observable resistance phenotype forms the basis of modern diagnostic microbiology. Genotypic methods detect specific resistance genes or mutations, while phenotypic methods measure the actual growth inhibition of a bacterial isolate under standardized conditions. These two approaches answer different questions, and their results do not always align.

The [World Health Organization](https://www.who.int/health-topics/antimicrobial-resistance) defines antimicrobial resistance as the ability of microorganisms to withstand antimicrobial treatments that were previously effective. This definition centers on the phenotypic outcome, the failure of a drug to inhibit bacterial growth. Genotypic resistance, by contrast, refers to the presence of genetic elements that encode resistance mechanisms. The correlation between these two levels of biological organization is imperfect, and understanding the sources of discordance is essential for accurate diagnosis, effective treatment, and meaningful surveillance.

For laboratory professionals and researchers, the practical challenge is interpreting discordant results without compromising patient care or research validity. A resistance gene detected by polymerase chain reaction or whole-genome sequencing does not automatically mean the isolate will display resistance in a susceptibility test. Conversely, an isolate showing phenotypic resistance may lack any known resistance gene, pointing to mechanisms that are not captured by current genomic databases.

### Why Genotype and Phenotype Can Disagree

The biological relationship between genotype and phenotype is mediated by gene expression, protein function, and environmental context. A resistance gene may be present but silent, either because it is not transcribed or because the encoded protein is not functional. Promoter mutations can abolish gene expression, while structural mutations can inactivate the enzyme or efflux pump that the gene encodes. In other cases, the gene is expressed but the resistance level is below the clinical breakpoint used to define susceptibility.

Research on [SHV beta-lactamases](https://pubmed.ncbi.nlm.nih.gov/32284385) illustrates how specific amino acid substitutions determine the resistance profile of an enzyme. The study identified positions in the SHV enzyme that are essential for extended-spectrum beta-lactamase activity and other positions that confer resistance to beta-lactamase inhibitors. Some substitutions produced latent resistance that only became apparent when combined with other changes or with a strong promoter. This finding demonstrates that the presence of a resistance gene allele does not predict its phenotypic impact without understanding the specific variant and its expression context.

The same principle applies to other resistance mechanisms. Efflux pumps can be upregulated by mutations in regulatory genes, producing resistance without the acquisition of a new resistance gene. Porin loss reduces drug entry into the bacterial cell, contributing to resistance in combination with other mechanisms. Target site mutations alter the binding of antimicrobial agents, and these changes are not always captured by resistance gene databases that focus on horizontally acquired determinants.

### The Clinical Significance of Discordance

Discordance between genotypic and phenotypic results has direct consequences for patient management. A clinical microbiologist who reports phenotypic susceptibility when a resistance gene is present may miss emerging resistance that could become clinically relevant during therapy. Conversely, reporting resistance based on genotypic data alone may deny patients an effective treatment option when the gene is not actually expressed.

The [review of Acinetobacter baumannii](https://pubmed.ncbi.nlm.nih.gov/42075708) emphasizes that the presence of resistance genes does not always translate directly into phenotypic resistance due to regulatory mechanisms, gene expression variability, and genomic context. Carbapenem-resistant A. baumannii is recognized as a critical priority pathogen, and accurate detection of resistance is essential for infection control and treatment decisions. The review calls for integrating phenotypic and genotypic approaches to capture the full resistance profile of clinical isolates.

For surveillance purposes, discordance complicates the interpretation of resistance trends. Genomic surveillance may overestimate resistance if it counts silent genes, or underestimate it if it misses resistance mechanisms that are not yet characterized. The [NCBI Pathogen Detection](https://www.ncbi.nlm.nih.gov/pathogens) database aggregates genomic data from foodborne and healthcare-associated pathogens, providing a resource for tracking resistance determinants. However, genomic data alone cannot replace phenotypic testing for clinical decision-making.

## Core Principles of Antimicrobial Susceptibility Testing

Phenotypic antimicrobial susceptibility testing measures the growth of a bacterial isolate in the presence of antimicrobial agents under standardized conditions. The minimum inhibitory concentration, or MIC, is the lowest concentration of an antimicrobial that prevents visible growth of the organism. This quantitative measure forms the basis for categorizing isolates as susceptible, intermediate, or resistant according to clinical breakpoints.

The [Clinical and Laboratory Standards Institute](https://clsi.org/standards/products/microbiology) publishes standards for antimicrobial susceptibility testing that define the methods, quality control requirements, and interpretive criteria used in clinical laboratories. These standards ensure that results are reproducible across laboratories and that clinical breakpoints reflect current pharmacokinetic and pharmacodynamic data. Adherence to these standards is essential for generating reliable phenotypic data that can be compared with genotypic results.

### Standard Phenotypic Methods

Several phenotypic methods are used in clinical and research laboratories. The disk diffusion method, also known as the Kirby-Bauer method, measures the zone of inhibition around disks impregnated with antimicrobial agents. Broth dilution methods determine the MIC by testing serial dilutions of an antimicrobial in liquid medium. Agar dilution methods incorporate antimicrobial agents into agar plates at defined concentrations. Gradient diffusion methods use a strip with a continuous concentration gradient to estimate the MIC.

Each method has advantages and limitations. Disk diffusion is simple and cost-effective for routine testing but provides only qualitative or semi-quantitative results. Broth microdilution is the reference method for many organism-drug combinations and provides quantitative MIC values. The choice of method depends on the organism, the antimicrobial agents being tested, and the laboratory resources available.

The [Bacteriological Analytical Manual](https://www.fda.gov/food/laboratory-methods-food/bacteriological-analytical-manual-bam) published by the U.S. Food and Drug Administration provides official methods for the analysis of foodborne pathogens. These methods include procedures for isolation, identification, and characterization of bacteria from food samples. While the manual focuses on food safety applications, the principles of quality control and method validation apply broadly to antimicrobial susceptibility testing.

### Quality Control in Susceptibility Testing

Quality control is essential for reliable phenotypic testing. Reference strains with known susceptibility profiles are tested alongside clinical isolates to verify that the test system is performing correctly. The [American Type Culture Collection](https://www.atcc.org/) provides authenticated reference strains that are used for quality control in clinical and research laboratories. These strains have documented susceptibility profiles that allow laboratories to validate their testing methods.

Quality control strains should be tested each day that susceptibility testing is performed, or according to the frequency specified in the testing standard. Results that fall outside the expected range indicate a problem with the test system, the reagents, or the technique. When quality control failures occur, patient results from that testing run should not be reported until the problem is resolved.

The [American Society for Microbiology](https://asm.org/) provides educational resources and professional guidance for laboratory practice, including best practices for antimicrobial susceptibility testing. These resources support the training of laboratory professionals and the implementation of quality systems in clinical microbiology laboratories.

## Genotypic Methods for Resistance Detection

Genotypic methods detect the presence of specific resistance genes or mutations directly in bacterial isolates or clinical specimens. These methods include polymerase chain reaction, DNA sequencing, and whole-genome sequencing. Genotypic approaches can provide rapid results and can detect resistance determinants that are difficult to assess phenotypically, such as in slow-growing organisms or mixed cultures.

### Polymerase Chain Reaction and Targeted Assays

Polymerase chain reaction amplifies specific DNA sequences, allowing the detection of known resistance genes. Multiplex PCR assays can detect multiple genes in a single reaction, making them efficient for screening common resistance determinants. Real-time PCR provides quantitative data and can be performed with minimal hands-on time.

Targeted assays are designed to detect specific genes or mutations that are known to confer resistance. These assays are rapid and sensitive but are limited to the targets included in the assay design. Novel resistance genes or mutations will not be detected by targeted approaches, creating a potential gap between genotypic and phenotypic results.

The [study of Riemerella anatipestifer](https://pubmed.ncbi.nlm.nih.gov/38471429) used PCR to identify isolates and whole-genome sequencing to characterize resistance genes. The study found a wide distribution of resistance genotypes among isolates from ducks and geese, with 88 resistance genes identified across 157 strains. The comparison of phenotype and genotype showed high correlation for most antimicrobial classes, but a notable difference for aminoglycoside resistance, where the presence of resistance genes did not always correspond to phenotypic resistance.

### Whole-Genome Sequencing

Whole-genome sequencing provides a complete picture of the genetic content of an isolate, including resistance genes, virulence factors, and mobile genetic elements. Bioinformatics tools can predict resistance phenotypes from genomic data by comparing the detected genes and mutations with curated databases. This approach can identify resistance determinants that are not included in targeted assays and can provide insights into the genetic context of resistance genes.

The [NCBI Pathogen Detection](https://www.ncbi.nlm.nih.gov/pathogens) platform integrates whole-genome sequencing data from foodborne and healthcare-associated pathogens. The platform identifies resistance genes and virulence factors and clusters related isolates to support outbreak investigations. This resource demonstrates the power of genomic approaches for surveillance, but it also highlights the need for phenotypic confirmation when genomic predictions are used for clinical decisions.

Genomic prediction of resistance is not always accurate. The presence of a resistance gene does not guarantee expression, and the absence of known resistance genes does not exclude resistance mediated by novel mechanisms. The [Acinetobacter baumannii review](https://pubmed.ncbi.nlm.nih.gov/42075708) notes that methodological differences in antimicrobial susceptibility testing standards and genomic prediction approaches can contribute to variability across studies. Standardized approaches are needed to improve the concordance between genotypic predictions and phenotypic results.

## Biological Mechanisms Behind Discordance

Understanding the biological mechanisms that cause genotype-phenotype discordance is essential for interpreting laboratory results and making clinical decisions. These mechanisms operate at multiple levels, from gene expression to protein function to bacterial population dynamics.

### Gene Expression and Regulation

A resistance gene may be present in the genome but not expressed under the conditions of the susceptibility test. Gene expression is regulated by promoters, regulatory proteins, and environmental signals. Mutations in promoter regions can increase or decrease gene expression, affecting the level of resistance. The [SHV beta-lactamase study](https://pubmed.ncbi.nlm.nih.gov/32284385) demonstrated that coupling a strong promoter to a beta-lactamase gene with a narrow-spectrum phenotype resulted in highly increased resistance to beta-lactamase inhibitors, cefepime, and ceftaroline. This finding shows that the same gene can produce different resistance profiles depending on its expression context.

Inducible resistance is another form of expression-dependent discordance. Some resistance genes are expressed only in the presence of the antimicrobial agent. If the susceptibility test does not include an inducing agent, the isolate may appear susceptible despite carrying a functional resistance gene. This phenomenon is well documented for inducible beta-lactamases in Gram-negative bacteria and for inducible macrolide resistance in Gram-positive bacteria.

### Mutations and Protein Function

Mutations in resistance genes can alter the function of the encoded protein. A mutation may abolish enzyme activity, change substrate specificity, or affect protein stability. The [SHV beta-lactamase study](https://pubmed.ncbi.nlm.nih.gov/32284385) identified specific amino acid positions that are essential for different resistance phenotypes. Substitutions at position 238 and 179 were essential for the extended-spectrum beta-lactamase phenotype, while substitution at position 69 was essential for beta-lactamase inhibitor resistance. Other substitutions conferred latent resistance that only became apparent under specific conditions.

Mutations in regulatory genes can also affect resistance by changing the expression of efflux pumps or other resistance mechanisms. These regulatory mutations are not always detected by resistance gene databases, which focus on the structural genes themselves. Whole-genome sequencing can identify regulatory mutations, but interpreting their phenotypic impact requires functional studies.

### Efflux Pumps and Membrane Permeability

Efflux pumps actively transport antimicrobial agents out of the bacterial cell, reducing intracellular drug concentrations. Many efflux pumps have broad substrate specificity and can contribute to resistance across multiple antimicrobial classes. Overexpression of efflux pumps can produce phenotypic resistance in the absence of a specific resistance gene.

Porins are channel proteins in the outer membrane of Gram-negative bacteria that allow the passage of hydrophilic molecules, including many antimicrobial agents. Loss or reduction of porin expression decreases drug entry into the cell, contributing to resistance. Porin loss often acts in combination with other resistance mechanisms, such as beta-lactamase production or efflux pump overexpression.

The [Acinetobacter baumannii review](https://pubmed.ncbi.nlm.nih.gov/42075708) identifies efflux pumps and resistance-associated genomic islands as important contributors to the complex resistance profile of this pathogen. The review emphasizes that the relationship between genotype and phenotype in A. baumannii is complicated by regulatory mechanisms and gene expression variability, making it difficult to predict phenotypic resistance from genomic data alone.

### Heteroresistance and Mixed Populations

Heteroresistance is the presence of a subpopulation of resistant cells within an isolate that is predominantly susceptible. This phenomenon can produce discordant results when different testing methods detect different subpopulations. A genotypic test may detect a resistance gene in the minority resistant population, while a phenotypic test may report susceptibility based on the majority susceptible population.

Heteroresistance has clinical significance because the resistant subpopulation can be selected during antimicrobial therapy, leading to treatment failure. Detection of heteroresistance requires specialized methods, such as population analysis profiling, that are not routinely performed in clinical laboratories. The presence of heteroresistance should be considered when phenotypic results are borderline or when treatment failure occurs despite apparent susceptibility.

## Practical Framework for Interpreting Discordant Results

When genotypic and phenotypic results disagree, a systematic approach is needed to determine the clinical significance of the discordance and to guide patient management. The following framework provides a structured method for evaluating discordant results in the clinical laboratory.

### Step 1: Verify the Phenotypic Result

Repeat the phenotypic susceptibility test using a validated method and appropriate quality control strains. Confirm that the isolate was correctly identified and that the test conditions met the requirements of the testing standard. Check that the antimicrobial agents tested are appropriate for the organism and that the results are interpreted using current clinical breakpoints.

If the repeat test confirms the original result, proceed to evaluate the genotypic data. If the repeat test gives a different result, investigate potential sources of variability, such as mixed cultures, contaminated reagents, or technical errors.

### Step 2: Evaluate the Genotypic Data

Confirm that the resistance gene was correctly identified and that the detection method was appropriate. Check the specificity of the primers or probes used in the assay and verify that the gene sequence matches the expected target. For whole-genome sequencing data, review the quality of the assembly and the annotation of resistance genes.

Consider whether the specific allele or variant of the resistance gene is known to confer resistance. The [SHV beta-lactamase study](https://pubmed.ncbi.nlm.nih.gov/32284385) demonstrates that different alleles of the same gene can have different resistance profiles. A gene that is present but has a mutation that inactivates the encoded protein will not produce phenotypic resistance.

### Step 3: Consider Alternative Resistance Mechanisms

If the genotypic data do not explain the phenotypic result, consider other mechanisms of resistance. Efflux pump overexpression, porin loss, and target site mutations can produce resistance without a detectable resistance gene. These mechanisms may require specialized testing, such as efflux pump inhibitor assays or sequencing of target genes.

The [uropathogenic Escherichia coli study](https://pubmed.ncbi.nlm.nih.gov/38357165) found that resistance to sulfonamide antibiotics was highly correlated with the presence of the sul2 gene, while resistance to aminoglycosides was correlated with the aac3-II gene. However, the study also found that biofilm formation and hemagglutinin activity were correlated with antibiotic resistance, suggesting that virulence factors and resistance mechanisms can be linked in ways that are not captured by simple genotypic analysis.

### Step 4: Assess Clinical Significance

Determine whether the discordance has clinical significance for the patient. Consider the site of infection, the severity of illness, the antimicrobial agents being used, and the availability of alternative treatments. A resistance gene that is not expressed may become clinically relevant if therapy selects for its expression or if the gene is transferred to another organism.

For surveillance purposes, discordant results should be documented and reported to the appropriate public health authorities. The [World Health Organization](https://www.who.int/health-topics/antimicrobial-resistance) emphasizes the importance of surveillance for tracking antimicrobial resistance trends and guiding stewardship interventions. Discordant results can provide early warning of emerging resistance mechanisms that are not yet captured by routine testing.

### Step 5: Document and Communicate

Document the discordant result, the investigation performed, and the final interpretation in the laboratory record. Communicate the findings to the clinical team, including the limitations of both genotypic and phenotypic approaches. Provide guidance on the clinical significance of the discordance and recommend appropriate follow-up testing or treatment adjustments.

Clear communication between the laboratory and the clinical team is essential for managing discordant results. The laboratory should provide context for the discordance, explain the implications for patient care, and recommend additional testing when appropriate.

## Records and Measurements for Discordance Monitoring

Systematic documentation of genotype-phenotype discordance is essential for quality improvement and for identifying emerging resistance mechanisms. Laboratories should maintain records of all discordant results, including the organism, the antimicrobial agent, the genotypic result, the phenotypic result, and the outcome of the investigation.

### Data Elements for Discordance Records

| Data Element | Description | Purpose |
|---|---|---|
| Organism identification | Species and strain information | Track discordance patterns by organism |
| Antimicrobial agent | Drug tested and class | Identify drugs with frequent discordance |
| Genotypic result | Gene or mutation detected | Compare with phenotypic outcome |
| Phenotypic result | MIC or category | Establish the reference result |
| Investigation outcome | Explanation for discordance | Build knowledge base for future cases |
| Clinical context | Infection site and patient status | Assess clinical significance |

### Tracking Discordance Rates

Laboratories can calculate discordance rates for specific organism-drug combinations by dividing the number of discordant results by the total number of isolates tested. High discordance rates may indicate problems with the genotypic assay, the phenotypic method, or the interpretation criteria. Investigating the causes of high discordance rates can identify opportunities for improving testing algorithms.

Discordance rates should be monitored over time to detect changes that may indicate emerging resistance mechanisms or problems with test performance. The [NCBI Pathogen Detection](https://www.ncbi.nlm.nih.gov/pathogens) platform provides a model for integrating genomic and phenotypic data for surveillance purposes. Similar approaches can be applied at the laboratory level to track discordance and improve the interpretation of resistance data.

## Common Failure Patterns in Discordance Interpretation

Several recurring patterns of error can compromise the interpretation of genotype-phenotype discordance. Recognizing these patterns can help laboratories avoid common mistakes and improve the accuracy of their reporting.

### Overreliance on Genotypic Results

Reporting phenotypic resistance based solely on the presence of a resistance gene can lead to incorrect treatment decisions. The [Acinetobacter baumannii review](https://pubmed.ncbi.nlm.nih.gov/42075708) emphasizes that the presence of resistance genes does not always translate directly into phenotypic resistance. Genotypic results should be interpreted in the context of the specific gene variant, its expression, and the organism's overall resistance profile.

### Overreliance on Phenotypic Results

Reporting phenotypic susceptibility without considering genotypic data can miss emerging resistance. A resistance gene that is present but not expressed under standard testing conditions may become clinically relevant during therapy. The [SHV beta-lactamase study](https://pubmed.ncbi.nlm.nih.gov/32284385) demonstrated that latent resistance can be activated by specific mutations or by changes in gene expression. Phenotypic results should be interpreted with awareness of the potential for hidden resistance mechanisms.

### Ignoring Quality Control Failures

Quality control failures can produce unreliable phenotypic results that lead to incorrect discordance interpretations. Laboratories should follow the quality control requirements of the [Clinical and Laboratory Standards Institute](https://clsi.org/standards/products/microbiology) and should not report patient results when quality control results are out of range. The [American Type Culture Collection](https://www.atcc.org/) provides authenticated reference strains for quality control testing.

### Failing to Consider Mixed Cultures

Mixed cultures can produce discordant results when different organisms in the sample have different resistance profiles. Genotypic testing may detect resistance genes from one organism, while phenotypic testing reflects the susceptibility of another. Careful examination of culture purity and accurate organism identification are essential for interpreting discordant results.

### Incomplete Investigation of Alternative Mechanisms

When genotypic data do not explain phenotypic resistance, laboratories may fail to investigate alternative mechanisms such as efflux pumps, porin loss, or target mutations. These mechanisms can be clinically significant and may require specialized testing. The [uropathogenic Escherichia coli study](https://pubmed.ncbi.nlm.nih.gov/38357165) found that multiple resistance mechanisms can be present in a single isolate, and the correlation between genotype and phenotype varies by antimicrobial class.

## Welfare and Safety Context for Laboratory Work

Laboratory work with antimicrobial-resistant bacteria requires appropriate biosafety practices to protect laboratory personnel and prevent the spread of resistant organisms. The [Biosafety in Microbiological and Biomedical Laboratories](https://www.cdc.gov/labs/bmbl/index.html) manual published by the CDC and NIH provides guidance for risk assessment, containment, and decontamination in laboratories working with infectious agents.

### Risk Assessment

Laboratories should conduct a risk assessment for each organism and procedure, considering the pathogenicity of the organism, the route of transmission, the concentration of the organism, and the procedures being performed. Antimicrobial-resistant organisms may require additional precautions because treatment options are limited and the consequences of laboratory-acquired infection are more severe.

The risk assessment should be documented and reviewed regularly, particularly when new organisms or procedures are introduced. The [American Society for Microbiology](https://asm.org/) provides professional guidance for biosafety in microbiology laboratories, including recommendations for working with antimicrobial-resistant organisms.

### Containment and Decontamination

Appropriate containment practices depend on the risk group of the organism and the procedures being performed. Biosafety cabinets should be used for procedures that generate aerosols, such as vortexing, sonication, or centrifugation. Personal protective equipment, including gloves, lab coats, and eye protection, should be worn when working with potentially infectious materials.

Decontamination procedures should be validated to ensure that they are effective against the organisms being handled. The [Biosafety in Microbiological and Biomedical Laboratories](https://www.cdc.gov/labs/bmbl/index.html) manual provides guidance for decontamination methods, including autoclaving, chemical disinfection, and other approaches. Waste disposal should follow institutional and regulatory requirements.

### Professional Escalation Criteria

Laboratory professionals should escalate concerns about biosafety or discordant results to appropriate supervisors or safety officers. Escalation is appropriate when:

- A quality control failure cannot be resolved
- A discordant result suggests a novel resistance mechanism
- A laboratory-acquired infection is suspected
- A biosafety concern is identified that cannot be resolved at the laboratory level

The [American Society for Microbiology](https://asm.org/) provides resources for laboratory professionals, including guidance for biosafety and professional practice. Laboratories should have clear protocols for escalation and should document all safety incidents and investigations.

## Limitations of Current Evidence

The evidence base for genotype-phenotype correlation in antimicrobial resistance has several limitations that affect the interpretation of discordant results.

### Methodological Variability

The [Acinetobacter baumannii review](https://pubmed.ncbi.nlm.nih.gov/42075708) notes that methodological differences in antimicrobial susceptibility testing standards and genomic prediction approaches can contribute to variability across studies. Different laboratories may use different testing methods, different breakpoints, or different bioinformatics pipelines, making it difficult to compare results across studies.

### Database Completeness

Resistance gene databases are incomplete, and novel resistance genes or mutations may not be represented. The [Riemerella anatipestifer study](https://pubmed.ncbi.nlm.nih.gov/38471429) identified 88 resistance genes among 157 strains, including genes from multiple resistance classes. The diversity of resistance genes in this single species highlights the challenge of maintaining comprehensive databases.

### Expression Context

The [SHV beta-lactamase study](https://pubmed.ncbi.nlm.nih.gov/32284385) demonstrated that the phenotypic impact of a resistance gene depends on its expression context, including promoter strength and the presence of other mutations. Genotypic data alone cannot predict the expression level of a resistance gene, and phenotypic testing remains essential for determining the actual resistance profile.

### Geographic and Temporal Variation

Resistance patterns vary by geographic region and change over time. The [Riemerella anatipestifer study](https://pubmed.ncbi.nlm.nih.gov/38471429) found no apparent regional pattern in the distribution of resistance genotypes among isolates from seven regions of China. However, the study also found that the isolates exhibited severe multiple antimicrobial resistance phenotypes, emphasizing the need for improved antimicrobial usage guidelines.

### Correlation with Clinical Outcomes

Most studies of genotype-phenotype correlation focus on laboratory measurements instead of clinical outcomes. The [uropathogenic Escherichia coli study](https://pubmed.ncbi.nlm.nih.gov/38357165) found correlations between resistance genes and phenotypic resistance, but did not assess whether these correlations predicted treatment success or failure. Clinical studies are needed to determine the prognostic significance of genotype-phenotype discordance.

## Professional Escalation and Reporting

When discordant results have potential clinical significance, laboratory professionals should escalate the findings to the appropriate clinical team and public health authorities. The [World Health Organization](https://www.who.int/health-topics/antimicrobial-resistance) emphasizes the importance of surveillance and reporting for antimicrobial resistance. Laboratories should have protocols for reporting unusual or concerning results.

### When to Escalate

Escalation is appropriate when:

- The discordance suggests a novel resistance mechanism that could affect public health
- The discordance affects a critical priority pathogen, such as carbapenem-resistant A. baumannii
- The discordance has implications for infection control
- The discordance cannot be resolved through routine investigation

The [Acinetobacter baumannii review](https://pubmed.ncbi.nlm.nih.gov/42075708) identifies carbapenem-resistant A. baumannii as a critical priority pathogen recognized by the World Health Organization. Discordant results for this organism should be escalated promptly because of the limited treatment options and the potential for nosocomial spread.

### Reporting to Public Health Authorities

Laboratories should report antimicrobial resistance data to public health authorities according to local and national requirements. The [NCBI Pathogen Detection](https://www.ncbi.nlm.nih.gov/pathogens) platform provides a mechanism for sharing genomic data from foodborne and healthcare-associated pathogens. Submission of discordant results to public health databases can support surveillance and research.

### Documentation for Clinical Decision-Making

The laboratory report should clearly document the genotypic and phenotypic results, the investigation performed, and the final interpretation. The report should note any limitations of the testing methods and should provide guidance for clinical decision-making. Clear communication with the clinical team is essential for ensuring that discordant results are interpreted correctly and that patient care is not compromised.

## Decision Matrix for Discordant Results by Organism and Drug Class

A practical decision matrix helps clinical microbiologists move from general discordance principles to specific action pathways. The matrix below organizes discordance management by organism group and drug class, because the biological mechanisms that cause genotype-phenotype mismatches differ substantially across these categories. This framework complements the stepwise investigation approach by providing a rapid reference for the most common clinical scenarios.

### Matrix Structure and Application

The decision matrix uses three input variables: the organism group, the drug class under evaluation, and the direction of discordance. Each cell in the matrix specifies the most likely biological explanation, the confirmatory test to perform, and the reporting action. The matrix assumes that basic quality control has already been verified and that the isolate has been correctly identified to species level.

| Organism Group | Drug Class | Gene Present, Susceptible Phenotype | Gene Absent, Resistant Phenotype |
|---|---|---|---|
| Enterobacterales | Beta-lactams | Check for promoter mutations or silent bla genes. Perform induction testing for AmpC producers. Report phenotypic result with comment. | Investigate porin loss combined with efflux overexpression. Perform combination disk testing. Escalate to reference method. |
| Enterobacterales | Aminoglycosides | Verify gene identity. Some aminoglycoside-modifying enzymes have weak activity. Report phenotypic result. | Test for 16S rRNA methyltransferases not in routine panels. Consider target site mutations. |
| Non-fermenting Gram-negatives | Carbapenems | Confirm carbapenemase gene allele. Check for expression silencing. Report phenotypic result with caution. | Investigate efflux pump overexpression and porin loss. Perform modified carbapenem inactivation method. Escalate for infection control. |
| Gram-positive cocci | Macrolides | Check for inducible resistance. Perform D-zone test. Report inducible resistance if positive. | Investigate ribosomal mutations or efflux pumps. Consider erm gene variants not detected by standard assays. |
| Gram-positive cocci | Glycopeptides | Verify van gene presence. Check for heteroresistance. Perform population analysis if available. | Investigate cell wall thickening or other intrinsic mechanisms. Escalate to reference laboratory. |

### Applying the Matrix to Specific Scenarios

The [Riemerella anatipestifer study](https://pubmed.ncbi.nlm.nih.gov/38471429) provides a useful example of how the matrix applies to veterinary pathogens. The study found high correlation between phenotype and genotype for most antimicrobial classes, but a notable difference for aminoglycoside resistance. In this scenario, the matrix directs the microbiologist to verify the aminoglycoside resistance gene identity and to consider whether the specific gene variant has weak enzymatic activity. The study identified 15 efflux pump resistance genes among the 157 strains, suggesting that efflux mechanisms may contribute to the aminoglycoside discordance.

For the [SHV beta-lactamase findings](https://pubmed.ncbi.nlm.nih.gov/32284385), the matrix addresses the scenario where a beta-lactamase gene is present but the isolate tests susceptible to cephalosporins. The study demonstrated that specific amino acid substitutions, such as M129V, A234G, S271I, and R292Q, conferred latent resistance to cefotaxime. The matrix directs the microbiologist to check the specific allele and to consider whether the gene is coupled to a strong promoter. The study showed that coupling a strong promoter to an A146V mutant resulted in highly increased resistance to beta-lactamase inhibitors, cefepime, and ceftaroline, but not to third-generation cephalosporins.

### Recording Matrix Outcomes

Each time the matrix is used, the outcome should be recorded in the laboratory discordance log. The record should include the organism, the drug class, the discordance direction, the suspected mechanism, the confirmatory test performed, and the final interpretation. Over time, these records reveal patterns that can guide updates to local testing algorithms.

The [Acinetobacter baumannii review](https://pubmed.ncbi.nlm.nih.gov/42075708) emphasizes that methodological differences in antimicrobial susceptibility testing standards and genomic prediction approaches contribute to variability across studies. Recording matrix outcomes at the local level helps laboratories understand how these methodological factors affect their own discordance rates. The review also notes that regulatory mechanisms and gene expression variability complicate the relationship between genotype and phenotype in A. baumannii, which the matrix addresses by directing investigation toward expression context.

### Limitations of the Matrix

The matrix is a decision support tool, not a substitute for professional judgment. It does not cover every organism-drug combination, and unusual isolates may require investigation beyond the matrix pathways. The matrix should be updated as new resistance mechanisms are described and as testing standards evolve.

The [Clinical and Laboratory Standards Institute](https://clsi.org/standards/products/microbiology) publishes updated standards for antimicrobial susceptibility testing, and laboratories should review these standards regularly to ensure that their matrix reflects current breakpoints and testing recommendations. The [American Society for Microbiology](https://asm.org/) provides educational resources that support the ongoing professional development needed to apply the matrix effectively.

### Integration with Laboratory Workflow

The matrix should be integrated into the laboratory workflow at the point where discordant results are first identified. A designated reviewer should apply the matrix and document the decision pathway. This reviewer should have sufficient experience to recognize when the matrix does not apply and when escalation to a senior microbiologist or reference laboratory is needed.

The [Bacteriological Analytical Manual](https://www.fda.gov/food/laboratory-methods-food/bacteriological-analytical-manual-bam) provides a model for how standardized decision pathways can be documented and implemented in microbiology laboratories. While the manual focuses on food safety applications, its approach to method validation and quality control applies broadly to antimicrobial susceptibility testing.

### Escalation Criteria Within the Matrix

The matrix includes escalation criteria for scenarios that require additional expertise or resources. Escalation is appropriate when the suspected mechanism involves a novel resistance determinant, when the discordance affects a critical priority pathogen, or when the discordance has potential implications for infection control. The [World Health Organization](https://www.who.int/health-topics/antimicrobial-resistance) recognizes carbapenem-resistant A. baumannii as a critical priority pathogen, and discordant results for this organism should be escalated promptly.

Escalation should also occur when the confirmatory tests specified in the matrix are not available in the laboratory. In these cases, the isolate should be referred to a reference laboratory that can perform the required testing. The [American Type Culture Collection](https://www.atcc.org/) provides authenticated reference strains that can be used to validate the performance of confirmatory tests before they are implemented in the routine workflow.

### Quality Assurance for Matrix Use

Laboratories should periodically audit their use of the matrix to ensure consistency and accuracy. The audit should review a sample of discordant cases to verify that the matrix was applied correctly, that the documentation is complete, and that the final interpretations were appropriate. Audit findings should be used to refine the matrix and to identify training needs for laboratory staff.

The [NCBI Pathogen Detection](https://www.ncbi.nlm.nih.gov/pathogens) platform provides a model for how standardized data collection and analysis can support quality assurance. Laboratories can use similar approaches to track their discordance rates and to compare their performance with regional or national benchmarks.

## Frequently Asked Questions

### Why would a bacterium carry a resistance gene but test as susceptible?

A resistance gene may be present but not expressed under the conditions of the susceptibility test. Promoter mutations can reduce or abolish gene expression, and structural mutations can inactivate the encoded protein. The [SHV beta-lactamase study](https://pubmed.ncbi.nlm.nih.gov/32284385) demonstrated that specific amino acid substitutions can change the resistance profile of an enzyme, and that promoter strength can affect the level of resistance produced by the same gene.

### How can phenotypic resistance occur without a detectable resistance gene?

Phenotypic resistance can arise from mechanisms that are not captured by resistance gene databases. Efflux pump overexpression, porin loss, and target site mutations can produce resistance without the acquisition of a new resistance gene. The [Acinetobacter baumannii review](https://pubmed.ncbi.nlm.nih.gov/42075708) identifies efflux pumps and regulatory mechanisms as important contributors to resistance that may not be detected by genotypic approaches.

### What is heteroresistance and how does it affect genotype-phenotype correlation?

Heteroresistance is the presence of a subpopulation of resistant cells within an isolate that is predominantly susceptible. Genotypic testing may detect a resistance gene in the minority resistant population, while phenotypic testing may report susceptibility based on the majority susceptible population. Heteroresistance can lead to treatment failure when the resistant subpopulation is selected during therapy.

### How should a laboratory investigate discordant genotypic and phenotypic results?

The laboratory should first verify the phenotypic result by repeating the susceptibility test with appropriate quality control. The genotypic data should then be evaluated to confirm the identity of the resistance gene and to check for mutations that could affect gene expression or protein function. Alternative resistance mechanisms should be considered if the genotypic data do not explain the phenotypic result.

### What is the role of whole-genome sequencing in genotype-phenotype correlation?

Whole-genome sequencing provides a complete picture of the genetic content of an isolate, including resistance genes, virulence factors, and mobile genetic elements. The [NCBI Pathogen Detection](https://www.ncbi.nlm.nih.gov/pathogens) platform integrates genomic data for surveillance purposes. However, genomic prediction of resistance is not always accurate, and phenotypic testing remains essential for clinical decision-making.

### How do efflux pumps contribute to genotype-phenotype discordance?

Efflux pumps actively transport antimicrobial agents out of the bacterial cell, and overexpression of efflux pumps can produce phenotypic resistance without a specific resistance gene. The [Acinetobacter baumannii review](https://pubmed.ncbi.nlm.nih.gov/42075708) identifies efflux pumps as important contributors to the resistance profile of this pathogen. Efflux pump activity can be assessed using inhibitor-based assays, but these are not routinely performed in clinical laboratories.

### What are the limitations of using resistance gene databases for predicting phenotype?

Resistance gene databases are incomplete and may not include novel resistance genes or mutations. The [Riemerella anatipestifer study](https://pubmed.ncbi.nlm.nih.gov/38471429) identified 88 resistance genes among 157 strains, demonstrating the diversity of resistance determinants in a single species. Additionally, the presence of a resistance gene does not predict its expression level, and the phenotypic impact depends on the specific gene variant and its genetic context.

### When should discordant results be reported to public health authorities?

Discordant results should be reported when they suggest a novel resistance mechanism, affect a critical priority pathogen, or have implications for infection control. The [World Health Organization](https://www.who.int/health-topics/antimicrobial-resistance) emphasizes the importance of surveillance for antimicrobial resistance. Laboratories should follow local and national reporting requirements and should document all discordant results in the laboratory record.

## Related Bacteriology Guides

- [Biological Foundation Models for Antimicrobial Peptide Discovery in Veterinary Pathogens](/knowledge/bacteria/general/biological-foundation-models-for-antimicrobial-peptide-discovery-in-veterinary-pathogens)
- [Aeromonas hydrophila in Aquaculture: Virulence Factors and Antimicrobial Resistance](/knowledge/bacteria/aquatic-bacteria/aeromonas-hydrophila-aquaculture-virulence-factors-antimicrobial-resistance)
- [Swine Bacterial Diseases: Colibacillosis, UTI, and Antimicrobial Resistance](/knowledge/bacteria/livestock-bacteria/swine-bacterial-diseases-colibacillosis-uti-antimicrobial-resistance)
- [Avian Enrofloxacin: Pharmacology, Clinical Use, and Resistance in Poultry](/knowledge/bacteria/avian-bacteria/avian-enrofloxacin)
- [Avian Colibacillosis: Pathogenesis, Diagnosis, and Antimicrobial Resistance Patterns in Poultry](/knowledge/bacteria/avian-bacteria/avian-colibacillosis-pathogenesis-diagnosis-antimicrobial-resistance-poultry)

## References and Further Reading

- [Biosafety in Microbiological and Biomedical Laboratories](https://www.cdc.gov/labs/bmbl/index.html). CDC and NIH.
- [Microbiology Resources](https://asm.org/). American Society for Microbiology.
- [Antimicrobial Resistance](https://www.who.int/health-topics/antimicrobial-resistance). World Health Organization.
- [Bacteriological Analytical Manual](https://www.fda.gov/food/laboratory-methods-food/bacteriological-analytical-manual-bam). U.S. Food and Drug Administration.
- [Antimicrobial Susceptibility Testing](https://clsi.org/standards/products/microbiology). Clinical and Laboratory Standards Institute.
- [Culture Collections](https://www.atcc.org/). American Type Culture Collection.
- [NCBI Pathogen Detection](https://www.ncbi.nlm.nih.gov/pathogens). National Center for Biotechnology Information.
- [Comparative analysis of antimicrobial resistance phenotype and genotype of Riemerella anatipestifer.](https://pubmed.ncbi.nlm.nih.gov/38471429). Veterinary microbiology, 2024.
- [A Genotype-Phenotype Correlation Study of SHV β-Lactamases Offers New Insight into SHV Resistance Profiles.](https://pubmed.ncbi.nlm.nih.gov/32284385). Antimicrobial agents and chemotherapy, 2020.
- [Phenotype-Genotype Discordance in Antimicrobial Resistance of Acinetobacter baumannii: Implications for Diagnostics and Surveillance.](https://pubmed.ncbi.nlm.nih.gov/42075708). Pathogens (Basel, Switzerland), 2026.
- [Relationship between antimicrobial resistance and virulence factors in uropathogenic Escherichia coli isolates from Ramadi, Iraq: phenotype and genotype identification.](https://pubmed.ncbi.nlm.nih.gov/38357165). African health sciences, 2023.

> This article is educational and does not replace validated laboratory procedures, clinical diagnosis, institutional biosafety review, or public-health guidance.